

CITATION REPORT

List of articles citing

Bisphosphonate mechanism of action

DOI: 10.1007/s11926-003-0085-6

Current Rheumatology Reports, 2003, 5, 65-74.

Source: <https://exaly.com/paper-pdf/34943754/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
151	Combining high-resolution micro-computed tomography with material composition to define the quality of bone tissue. 2003 , 1, 11-9		59
150	Mechanism of action of bisphosphonates. 2003 , 1, 45-52		128
149	Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. 2003 , 13, 3231-5		57
148	Primitive adult hematopoietic stem cells can function as osteoblast precursors. 2003 , 100, 15877-82		143
147	Runx2/Cbfa1: a multifunctional regulator of bone formation. 2003 , 9, 2677-85		132
146	Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?. 2004 , 47, 1488-92		72
145	Intravenous bisphosphonate therapy for osteoporosis: where do we stand?. 2004 , 2, 24-30		7
144	Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer. 2004 , 19, 627-40		18
143	Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. 2004 , 2, 6		76
142	The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. 2004 , 35, 418-24		76
141	Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. 2004 , 103-9		79
140	Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 , 16, 419-27		88
139	Does osteopenia warrant treatment?. 2005 , 12, 639-48		9
138	HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. 2005 , 106, 4294-302		56
137	¹⁸⁸ Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases. 2005 , 62, 541-9		25
136	Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC). 2005 , 23, 1004-12		26
135	Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. 2005 , 15, 4685-90		59

134	Rheumatic diseases: the effects of inflammation on bone. 2005 , 208, 228-51		301
133	New Insights into the Chemistry of gem-Bis(phosphonates): Unexpected Rearrangement of Michael-Type Acceptors. 2005 , 2005, 3687-3696		16
132	Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. <i>Osteoporosis International</i> , 2005 , 16, 1989-98	5.3	17
131	Risedronate-induced intravascular haemolysis complicated by acute tubular necrosis. 2005 , 24, 665-6		2
130	Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. 2005 , 62, 275-81		26
129	Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. 2005 , 25, 651-4		52
128	Abnormalities of vasomotor regulation in the pathogenesis of the acute charcot foot of diabetes mellitus. 2005 , 4, 133-7		25
127	Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. 2005 , 76, 1113-22		118
126	Autoactivation profiles of calcium-dependent matrix metalloproteinase-2 and -9 in inflammatory synovial fluid: effect of pyrophosphate and bisphosphonates. 2005 , 358, 182-91		17
125	Chemotherapy-induced ovarian failure: manifestations and management. 2005 , 28, 401-16		91
124	Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. 2006 , 70, 147-53		46
123	Treating osteoporosis: economic aspects of bisphosphonate therapy. 2006 , 7, 1457-67		3
122	Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase. 2006 , 580, 5723-7		15
121	Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. 2006 , 29, 151-60		11
120	[Metabolic bone disease: something more than medication]. 2006 , 206, 465-6; author reply 466-7		
119	R β lica. 2006 , 206, 466-467		
118	In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation. 2006 , 19, 309-17		17
117	Skeletal complications and the use of bisphosphonates in metastatic prostate cancer. 2006 , 12, 462-9		4

116	Tissue engineering strategies for the future generation of dental implants. 2006 , 41, 157-76	31
115	The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. 2006 , 1068, 543-56	52
114	Strategies for the prevention and treatment of osteoporosis during early postmenopause. 2006 , 194, S12-23	86
113	Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy. <i>Journal of Bone and Mineral Metabolism</i> , 2006 , 24, 467-75	2.9 13
112	Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. 2006 , 21, 924-9	42
111	Treatment strategies for skeletal complications of cancer. 2006 , 5, 1074-7	17
110	Progresses in the field of drug design to combat tropical protozoan parasitic diseases. 2006 , 13, 335-60	92
109	Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?. 2006 , 17, 1197-204	88
108	Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. 2006 , 103, 4729-34	69
107	Current status and progresses made in malaria chemotherapy. 2007 , 14, 289-314	45
106	Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates. 2007 , 7, 132-5	8
105	Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. 2007 , 57, 247-52	29
104	The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. 2007 , 4, 1	52
103	Osteoporosis and periodontal disease. 2007 , 44, 29-43	31
102	Synthesis of bisphosphonate derivatives of ATP by T4 DNA ligase, ubiquitin activating enzyme (E1) and other ligases. 2008 , 75, 1959-65	9
101	Bisphosphonates activate the 5-fluorouracil/uracil phosphoribosyltransferase activity present in <i>Saccharomyces cerevisiae</i> cell extracts: implications for tumor treatments. 2008 , 76, 825-30	0
100	The osteoclast: friend or foe?. 2008 , 3, 457-84	266
99	Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival. 2008 , 106, 547-54	21

98	O alendronato de sódio na prevenção da osteopenia secundária à imobilização gessada, em ratas: avaliação histomorfométrica. 2008 , 43, 442-451		2
97	Synthesis of ATP derivatives of compounds of the mevalonate pathway (isopentenyl di- and triphosphate; geranyl di- and triphosphate, farnesyl di- and triphosphate, and dimethylallyl diphosphate) catalyzed by T4 RNA ligase, T4 DNA ligase and other ligases Potential relationship with the effect of bisphosphonates on osteoclasts. 2009 , 78, S35-43		11
96	Complexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapy. 2009 , 67, 11-3		29
95	The posttranslational processing of prelamin A and disease. 2009 , 10, 153-74		102
94	CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature. 2009 , 18, 492-500		19
93	Bone Health. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009 , 31, S34-S41	1.3	1
92	Zoledronate reduces unwanted bone resorption in intercalary bone allografts. 2010 , 34, 599-603		11
91	Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. 2010 , 87, 469-84		73
90	Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. 2010 , 14, 59-64		33
89	Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice. 2010 , 80, 352-61		34
88	Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2582-91	6.3	29
87	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). 2010 , 18, 2428-38		21
86	Effects of alendronate on bone healing after tooth extraction in rats. 2010 , 16, 674-85		69
85	Past, present and future of therapies in pediatric sarcomas. 2010 , 6, 605-18		4
84	Optimal management of cancer treatment-induced bone loss: considerations for elderly patients. 2011 , 28, 867-83		11
83	Osteonecrose maxilofacial induzida por bisfosfonatos em indivíduos com osteoporose. 2011 , 46, 495-499		2
82	BISPHOSPHONATE-INDUCED MAXILLOFACIAL OSTEONECROSIS IN OSTEOPOROTIC INDIVIDUALS. 2011 , 46, 495-9		2
81	Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. <i>Osteoporosis International</i> , 2011 , 22, 1927-34	5.3	10

80	The Shortest Strategy for Generating Phosphonate Prodrugs by Olefin Cross-Metathesis □ Application to Acyclonucleoside Phosphonates. 2011 , 2011, 7324-7330		14
79	Binding affinity of surface functionalized gold nanoparticles to hydroxyapatite. 2011 , 99, 58-66		49
78	Synthesis, modelling and kinetic assays of potent inhibitors of purple acid phosphatase. 2011 , 21, 3092-4		20
77	ONJ in two dental practice-based research network regions. 2011 , 90, 433-8		40
76	Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?. 2011 , 93, 1289-95		39
75	LIBP-Pred: web server for lipid binding proteins using structural network parameters; PDB mining of human cancer biomarkers and drug targets in parasites and bacteria. 2012 , 8, 851-62		13
74	Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (<i>Oryzomys palustris</i>) with periodontitis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 2130-43	6.3	93
73	Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. 2012 , 148, 307-14		27
72	Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. 2012 , 8, 253-66		13
71	Comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis. 2012 , 285, 1019-23		4
70	Penicillin inhibitors of purple acid phosphatase. 2012 , 22, 2555-9		9
69	Fourier transform infrared imaging as a tool to chemically and spatially characterize matrix-mineral deposition in osteoblasts. 2013 , 92, 50-8		7
68	Osteoporosis and treatments in Japan: management for preventing subsequent fractures. <i>Journal of Bone and Mineral Metabolism</i> , 2013 , 31, 367-80	2.9	15
67	High sensitivity LC-MS/MS method for direct quantification of human parathyroid 1-34 (teriparatide) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 938, 96-104	3.2	24
66	Osteoclast-induced Foxp3+ CD8 T-cells limit bone loss in mice. 2013 , 56, 163-73		34
65	Decreased bone mineral density and periodontal management. 2013 , 61, 195-218		28
64	Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections. 2013 , 4, 476-492		48
63	Atypical femoral fractures: a review of the literature. 2013 , 11, 179-87		20

62	Atypical femoral fractures: what do we know about them?: AAOS Exhibit Selection. 2013 , 95, e8 1-13		62
61	Reproductive and Hormonal Issues in Women with Autoimmune Diseases. 2013 , 473-483		0
60	Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis. 2014 , 45, 570-9		4
59	Pharmacologic augmentation of implant fixation in osteopenic bone. 2014 , 12, 55-64		16
58	Antiresorptive drug-related osteonecrosis of the jaw. 2014 , 58, 369-84		30
57	Thermodynamic evaluation of the binding of bisphosphonates to human farnesyl pyrophosphate synthase. 2014 , 62, 77-83		7
56	Impaired Fracture Healing Caused by Deficiency of the Immunoreceptor Adaptor Protein DAP12. 2015 , 10, e0128210		11
55	Prevention and treatment of bone fragility in cancer patient. 2015 , 12, 116-29		16
54	The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue. 2015 , 2, 8-13		20
53	Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. <i>Osteoporosis International</i> , 2015 , 26, 327-37	5.3	6
52	A Trimodality Comparison of Volumetric Bone Imaging Technologies. Part II: 1-Yr Change, Long-Term Precision, and Least Significant Change. 2015 , 18, 260-9		6
51	Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates. <i>Journal of Oral and Maxillofacial Surgery</i> , 2015 , 73, 1095-105	1.8	26
50	Atypical femur fracture during bisphosphonate drug holiday: a case series. <i>Osteoporosis International</i> , 2015 , 26, 1755-8	5.3	11
49	Successful conservative treatment: multiple atypical fractures in osteoporotic patients after bisphosphate medication: a unique case report. <i>Medicine (United States)</i> , 2015 , 94, e446	1.8	5
48	Alendronate-Associated Osteonecrosis of the Hard Palate After Harvesting of a Connective Tissue Graft: A Case Report. <i>Clinical Advances in Periodontics</i> , 2015 , 5, 171-177	0.9	1
47	Small molecules and their controlled release that induce the osteogenic/chondrogenic commitment of stem cells. <i>Biotechnology Advances</i> , 2015 , 33, 1626-40	17.8	38
46	Bisphosphonates: Possible Modes of Action and Implications for Dental Implant Treatment. A Review of the Literature <i>Journal of General Practice (Los Angeles, Calif)</i> , 2016 , 03,		0
45	Repetitive Stress Pathology: Bone. 2016 , 913-937		

44	Effectiveness of alendronate as an adjunct to scaling and root planing in the treatment of periodontitis: a meta-analysis of randomized controlled clinical trials. <i>Journal of Periodontal and Implant Science</i> , 2016 , 46, 382-395	2	6
43	Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 336-40	6.3	55
42	Ostéoporose pendant la ménopause. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016 , 38, S465-S483	1.3	
41	Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 359-70	2.2	13
40	Establishment of a 3D-dynamic osteoblasts-osteoclasts co-culture model to simulate the jawbone microenvironment in vitro. <i>Life Sciences</i> , 2016 , 152, 82-93	6.8	22
39	Assembling of electrospun meshes into three-dimensional porous scaffolds for bone repair. <i>Biofabrication</i> , 2017 , 9, 015018	10.5	16
38	Bisphosphonates and atypical subtrochanteric fractures of the femur. <i>Bone and Joint Research</i> , 2017 , 6, 144-153	4.2	27
37	Pharmacokinetics in Intact Rats of N,N,N',N'-Ethylenediaminetetrakis-(Methylenephosphonic Acid) Labeled with Gallium-68. <i>Pharmaceutical Chemistry Journal</i> , 2017 , 51, 331-336	0.9	
36	Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. <i>Nanomedicine</i> , 2017 , 12, 2083-2095	5.6	19
35	The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration. <i>Odontology / the Society of the Nippon Dental University</i> , 2017 , 105, 382-390	3.6	12
34	Diethylalkylsulfonamido(4-methoxyphenyl)methyl)phosphonate/phosphonic acid derivatives act as acid phosphatase inhibitors: synthesis accompanied by experimental and molecular modeling assessments. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017 , 32, 20-28	5.6	6
33	Anti-Resorptive Therapy. 2017 , 251-259		
32	Development of Bone Targeting Drugs. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	46
31	Short-term daily teriparatide in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018 , 28, 468-473	4.3	1
30	Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw. <i>Nuclear Medicine and Molecular Imaging</i> , 2018 , 52, 311-317	1.9	2
29	Bioceramics as drug delivery systems. 2018 , 153-194		1
28	Non-Viral Delivery System and Targeted Bone Disease Therapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	14
27	Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat. <i>Journal of Veterinary Internal Medicine</i> , 2019 , 33, 862-867	3.1	7

26	Bioactive injectable triple acting thermosensitive hydrogel enriched with nano-hydroxyapatite for bone regeneration: in-vitro characterization, Saos-2 cell line cell viability and osteogenic markers evaluation. <i>Drug Development and Industrial Pharmacy</i> , 2019 , 45, 787-804	3.6	15
25	Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. <i>Journal of Bone and Mineral Metabolism</i> , 2019 , 37, 805-814	2.9	11
24	Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates. <i>Journal of Experimental Orthopaedics</i> , 2019 , 6, 41	2.3	6
23	Effect of TNF inhibitors on bone mineral density in rheumatoid arthritis patients receiving bisphosphonate: a retrospective cohort study. <i>Rheumatology International</i> , 2020 , 40, 481-487	3.6	6
22	Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs. <i>Molecules</i> , 2020 , 25,	4.8	8
21	Osteoporosis and Spine Surgery: A Critical Analysis Review. <i>JBJS Reviews</i> , 2020 , 8, e0160	2.6	1
20	Osteoporosis and the Potential of Cell-Based Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	25
19	Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
18	Bisphosphonates pathway. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 50-3	1.9	36
17	Heteroatom-substituted gem-Bisphosphonates: Advances in the Synthesis and Prospects for Biomedical Application. <i>Current Organic Chemistry</i> , 2019 , 23, 530-615	1.7	6
16	Cancer treatment-related bone loss: a review and synthesis of the literature. <i>Current Oncology</i> , 2008 , 15, S30-40	2.8	33
15	Osteoporosis: "A risk factor for periodontitis". <i>Journal of Indian Society of Periodontology</i> , 2009 , 13, 90-61.1	1.1	15
14	Effect of TNF inhibitors with bisphosphonates vs bisphosphonates alone on bone mineral density and bone and cartilage biomarkers at 1 year in patients with rheumatoid arthritis: A prospective study.. <i>Modern Rheumatology</i> , 2021 ,	3.3	
13	Effect of Azithromycin on Mineralized Nodule Formation in MC3T3-E1 Cells. <i>Current Issues in Molecular Biology</i> , 2021 , 43, 1451-1459	2.9	0
12	Actualizaci3n de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisi3n de literatura. <i>Revista A D M</i> , 2020 , 77, 197-202	0.2	1
11	Aromatase inhibitors and bone loss. <i>Oncology</i> , 2006 , 20, 1029-39; discussion 1039-40, 1042, 1048	1.8	27
10	Bioanalytical method development and validation of highly selective and sensitive LC-MS/MS method for determination of teriparatide (parathyroid hormone fragment 1-34) in human serum through direct detection of intact teriparatide molecule. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1187, 123046	3.2	0
9	A Polymer-Nanoparticles Drug Delivery System Co-Delivering Artesunate and Alendronate for Local Therapy of Breast Cancer Metastatic Osteolysis. <i>SSRN Electronic Journal</i> ,	1	1

8	The effect of bisphosphonate and intermittent human parathyroid hormone 1-34 treatments on cortical bone allografts in rabbits. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 139-45	5.2	4
7	Effects of periodontal and bisphosphonate treatment on the gingival crevicular levels of sclerostin and dickkopf-1 in postmenopausal osteoporosis with and without periodontitis. <i>Journal of Periodontal Research</i> ,	4.3	0
6	Cellular Carcinogenesis: Role of Polarized Macrophages in Cancer Initiation. <i>Cancers</i> , 2022 , 14, 2811	6.6	0
5	Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases.		0
4	IFN- γ mediates the anti-osteoclastic effect of bisphosphonates and dexamethasone. 13,		0
3	From Stem to Sternum: The Role of Shp2 in the Skeleton.		0
2	RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. 2023 , 24, 3014		1
1	MicroRNA in medication related osteonecrosis of the jaw: a review. 14,		0